Soleno Therapeutics Secures $50M Credit Facility
Ticker: SLNO · Form: 8-K · Filed: 2024-06-20T00:00:00.000Z
Sentiment: neutral
Topics: financing, debt, credit-facility
TL;DR
SolenO just inked a $50M credit deal, drawing $25M immediately. Big cash infusion!
AI Summary
On June 13, 2024, Soleno Therapeutics, Inc. entered into a Material Definitive Agreement, specifically a Second Amendment to the Second Amended and Restated Credit Agreement. This amendment involves a new term loan facility of up to $50 million, with an initial tranche of $25 million drawn on June 13, 2024.
Why It Matters
This new credit facility provides Soleno Therapeutics with significant financial flexibility, potentially enabling them to fund ongoing operations and strategic initiatives, such as the advancement of their pipeline.
Risk Assessment
Risk Level: medium — While the new credit facility provides capital, the company's stage and the inherent risks of drug development mean significant financial and operational risks remain.
Key Numbers
- $50.0M — Credit Facility (Maximum amount available under the new term loan facility.)
- $25.0M — Initial Draw (Amount drawn on the new term loan facility on June 13, 2024.)
Key Players & Entities
- Soleno Therapeutics, Inc. (company) — Registrant
- Second Amendment to the Second Amended and Restated Credit Agreement (agreement) — Material Definitive Agreement
- $50 million (dollar_amount) — New term loan facility amount
- $25 million (dollar_amount) — Initial tranche drawn
- June 13, 2024 (date) — Date of agreement and initial draw
FAQ
What is the purpose of the new $50 million term loan facility?
The filing indicates the new term loan facility is part of a Second Amendment to the Second Amended and Restated Credit Agreement, providing additional capital for the company.
When was the initial tranche of the new credit facility drawn?
An initial tranche of $25 million was drawn on June 13, 2024.
What specific agreement was amended?
The agreement amended was the Second Amended and Restated Credit Agreement, through a Second Amendment.
What is the total potential borrowing capacity under this new facility?
The total potential borrowing capacity under the new term loan facility is up to $50 million.
What is the name of the company filing this report?
The company filing this report is Soleno Therapeutics, Inc.
Filing Stats: 475 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2024-06-20 16:17:53
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by
- $57,400 — base monthly rent payments beginning at $57,400 that increase annually by approximately
Filing Documents
- d839332d8k.htm (8-K) — 22KB
- 0001193125-24-164463.txt ( ) — 141KB
- slno-20240613.xsd (EX-101.SCH) — 3KB
- slno-20240613_lab.xml (EX-101.LAB) — 18KB
- slno-20240613_pre.xml (EX-101.PRE) — 11KB
- d839332d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SOLENO THERAPEUTICS, INC. Date: June 20, 2024 By: /s/ Anish Bhatnagar Anish Bhatnagar Chief Executive Officer